Searched for
CDMO PLAYERS
India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- The 30% smallcap tilt: How Abakkus Flexi Cap Fund is positioning for the next rallyAbakkus Mutual Fund is strategically allocating 30% to smallcaps within its Flexi Cap Fund, identifying mispriced opportunities despite str...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Crude awakening: Chemical companies face margin pressure as oil-linked costs surge amid geopolitical tensionsRising crude oil prices are pressuring chemical sector margins due to increased feedstock and energy costs. Despite this, the Nifty Chemica...
- Geopolitical tensions keep markets nervous despite strong earnings: Dipan MehtaGeopolitical tensions, particularly the Iran crisis, are overshadowing strong corporate earnings, according to Dipan Mehta. While India Inc...
- Cohance Lifesciences shares slip 7% after Jefferies cuts target price, downgrades on weak Q4Cohance Lifesciences shares dropped significantly after reporting an 84% year-on-year decline in March-quarter net profit. Jefferies downgr...
- Earnings season is strong, but Q1 pain is coming: Dipan MehtaMarket expert Dipan Mehta finds India's current earnings season strong. He notes that future quarters will test corporate India due to pote...
- Crude shock temporary; pharma and EMS are the real bets: Abhay AgarwalGeopolitical fears are driving crude oil prices higher, but Piper Serica's Abhay Agarwal believes this is a temporary, sentiment-driven spi...
- Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang VohraShares of Cohance Lifesciences surged 20% on Monday after the appointment of former Cipla CEO Umang Vohra as its new Executive Chairman and...
- Now is the time to start deploying money into markets, says Nitin Raheja; here's where to lookIndian markets present attractive long-term investment opportunities following recent corrections, according to Nitin Raheja of Julius Baer...
- STCH bets on AI to fix trial-and-error in fabric R&D, raises $5.5 million from Omnivore, Kae CapitalSTCH is revolutionizing fabric development with AI. The company helps fashion brands design and source materials efficiently. This platform...
- Why smallcap funds are still a buy: A long-term strategy from Aditya KhemaniSmallcap valuations seem high but underlying fundamentals have improved. Aditya Khemani of Invesco Mutual Fund sees this as a structural sh...
- Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocksThe US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...
- Which pharma companies will benefit from latest government policies? Sumit Gupta explainsThe Indian pharmaceutical sector is poised for growth, driven by government support for R&D and manufacturing. Policies promoting bulk drug...
- Foram Parekh on what to bet on in pharma packForam Parekh shares insights on CDMO companies' positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about L...
- Merger effect! Suven Pharma shares jump 15% in 2 daysAfter the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every...
- Suven Pharmaceuticals shares soar 13% on proposed merger with Cohance LifesciencesShares of Suven Pharmaceuticals surged 13% on the NSE after proposing a merger with Cohance Lifesciences to strengthen its CDMO industry po...
- Suven-Cohance Lifesciences merger announced to create 1st listed PE-led contract manufacturer in Indian pharmaSuven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is w...
- Suven Pharma, Cohance Lifesciences to merge to bolster CDMO businessPromoter of Suven Pharma, Advent International, had said last year that it would merge the two businesses post the buyout of its significan...
Load More
